LIGAND PHARMACEUTICALS INC business relationships

Companies named in LIGAND PHARMACEUTICALS INC’s 10-K filed 2026-02-27, and public companies whose annual reports name LIGAND PHARMACEUTICALS INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.1 / 10
AI naming: 100 / 100
Agent readiness: 30 / 100
AI adoption: 0 / 100

Named in LIGAND PHARMACEUTICALS INC’s annual report 12

AMGEN INC (AMGN)Partner7.7
“Revenues from sales of Captisol material to our collaboration partners, including Amgen, represent approximately half of our royalty revenues.” SEC filing
BRISTOL MYERS SQUIBB CO (BMY)Partner7.7
“...and 31.875 % of the future licensed milestones paid to Agenus on six-partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), a...” SEC filing
GILEAD SCIENCES, INC. (GILD)Partner7.7
“...ed milestones paid to Agenus on six-partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royal...” SEC filing
Merck & Co., Inc. (MRK)Partner7.7
“...programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royalty on future global net sales of Agenus' novel immuno-...” SEC filing
BAXTER INTERNATIONAL INC (BAX)Licensor6.7
“We have a license agreement with Baxter, related to Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada.” SEC filing
Sanofi (SNY)Partner6.7
“...ner programs: 1) a single-digit royalty on global net sales of AT220, an Arestat®-enhanced biosimilar product marketed by a global pharmaceutical company; and 2) potential annual technology access fees and milestones from AT292 (efdoralprin alfa/SAR447537/INBRX-101), a partnered program with Sanofi.” SEC filing
INCYTE CORP (INCY)Partner6.1
“...partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royalty on future global net sales of Age...” SEC filing
UroGen Pharma Ltd. (URGN)Partner5.4
“...BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royalty on future global net sales of Agenus' novel immuno-oncology botensilimab...” SEC filing
CASI Pharmaceuticals (CASIF)Licensee4.6
“We supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the United States, and CASI Pharmaceuticals for sales in China.” SEC filing
CASI Pharmaceuticals (CASIF)Licensor4.6
“Under the terms of the license agreement, Acrotech Biopharma has marketing rights worldwide excluding China, and CASI Pharmaceuticals has marketing rights in China.” SEC filing
EvomelaPartner4.2
“Several third parties have challenged, and additional third parties may challenge, the patents covering our partner's branded products, including Kyprolis and Evomela, which could result in the invalidation or unenforceability of some or all of the relevant patent claims.” SEC filing
Arecor LimitedSupplier4.2
“On September 24, 2025, we invested $ 7 million to purchase economic rights from Arecor Limited ("Arecor"), with an additional $ 1 million in deferred consideration payable in two equal parts at the six- and twelve-month anniversaries of the transaction closing date.” SEC filing

Companies whose annual reports name LIGAND PHARMACEUTICALS INC 6

NOVARTIS AG (NVS)names it as licensor7.7
“Promacta / Revolade is marketed under a research, development and license agreement between Novartis and RPI Finance Trust (dba Royalty Pharma), as assignee of Ligand Pharmaceuticals.” SEC filing
TG THERAPEUTICS, INC. (TGTX)names it as licensor5.4
“License Agreement by and between TG Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated, dated June 23, 2014 (incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q for the quarter ended June 30, 2014).*” SEC filing
Pelthos Therapeutics Inc. (PTHS)names it as partner4.7
“current API theoretical manufacturing capacity could be roughly doubled, if needed, due to one or more of the following: a higher than expected sales demand for ZELSUVMI, demand from current partners, such as Ligand, and potential future partnerships for ZELSUVMI and/or the NITRICIL platform.” SEC filing
Viking Therapeutics, Inc. (VKTX)names it as licensor4.7
“We are substantially dependent on technologies we licensed from Ligand Pharmaceuticals Incorporated, or Ligand, and if we lose the license to such technologies or our master license agreement with Ligand, or the Master License Agreement, is terminated for any reason, our ability to develop existing...” SEC filing
LeonaBio, Inc. (LONA)names it as licensor4.2
“License Agreement between Ligand Pharmaceuticals Incorporated and Athira Pharma, Inc. dated December 18, 2025” SEC filing
LeonaBio, Inc. (LONA)names it as partner4.2
“Lasofoxifene was discovered through a research collaboration between Pfizer Inc. ("Pfizer") and Ligand Pharmaceuticals ("Ligand").” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.